Hormonal
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide produce significant weight loss and improve cardiovascular outcomes by acting as incretin mimetics that target G-protein-coupled receptors to regulate body fat and energy balance.
GLP-1 medications like semaglutide are highly effective for significant weight loss (approx. 15%) when combined with a reduced-calorie diet. They work by mimicking gut hormones to reduce appetite and slow digestion. Treatment requires weekly injections and gradual dose escalation to manage side effects like nausea. Because obesity is chronic, long-term use is often necessary to maintain results.
These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein–coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance.
Why this rating
The claims are supported by multiple large-scale Phase III RCTs (STEP, SCALE, SURPASS) and meta-analyses cited in the review.
Source
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Jang Won Son et al. · Endocrinology and Metabolism · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →